Many hospitals in Italy, Spain and China are now treating COVID-19 with reportedly “excellent”, “spectacular” results. Reports of these treatments appear in Italian and Spanish local news outlets but seem to be virtually unknown outside these regions. I’m trying to gather the information as it appears and collect it on this page, as well as other raw notes. Much of this is translated from Italian, Spanish or German.
Current clinical trials:
Current running trials I’ve found are:
- NCT04366089 Started 2020-03-26, Rome. Randomized controlled, single-blind on outcomes assessor. ~152 participants. Treatment group receives systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days, plus standard of care. Control group receives standard of care. (Standard of care includes hydroxychloroquine and antibiotics.)
- ChiCTR2000030165 Started 2020-02-22, Haihe Hospital, Tianjin. Non-random controlled. 15 mild ill and 15 severe or critical ill patients receive conventional treatment plus ozonated autohaemotherapy; 30 controls receive conventional treatment.
- NCT04359303 Starting April 2020, Valencia, Spain. Randomized controlled double-blind. ~50 participants. Treatment group receive WHO-recommended treatment plus autohaemotherapy: 200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patient’s blood. Controls receive WHO-recommended treatment.
- NCT04370223 Starting ~2020-05-04, Clinica Nuestra Señora del Rosario, Ibiza. Randomized controlled open-label. ~208 participants, all with COVID-19 pneumonia. Treatment group receive standard hospital treatment plus autohaemotherapy every 12 hours during 5 days (100-200ml of patient’s blood interacted with 200ml gas containing 40 μg/mL ozone). Controls receive standard hospital treatment.
- NCT04388514 Started 2020-04-08; 90 participants, all with COVID-19 pheumonia: randomized 45 with standard of care plus blood ozonation; 45 with standard of care. Single-blind (investigator). Measuring time of respiratory improvement and weaning from O2 support, length of hospitalization, length of ICU support, improvement in chest imaging, improvement in cytochine release syndrome (measuring IL-6, lymphocyte typing for CD4, CD3, CD8, HLA-DR, CD45)
- NCT04400006 studying ozone therapy as a preventative. Started 2020-05-06, Marmara University Istanbul, Turkey. Phone survey of adults who have received at least 10 major autohaemotherapy treatments in the 6 months prior to first reported Turkish COVID-19 case.
- https://www.irct.ir/trial/47149 Starting ~2020-04-23, Baqiyatallah University of Medical Sciences, Iran. Randomized, controlled, non-blinded. Target of 80 participants. Treatment group receive ozone major autohaemotherapy (100-200cc blood interacted with equal volume of 35μg/mL ozone; volume depending on severity) 1-2 times daily depending on severity of disease, plus conventional treatment. Controls receive conventional treatment.
Two other trials (apparently failed to receive ethics approval? not sure if these are running or not): ChiCTR2000030006 and ChiCTR2000030102
Medical/scientific articles and letters on ozone therapy:
Study results reporting positive outcomes:
- Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported in ScienceDirect journal International Immunopharmacology. 50 men over 60 years of age with COVID-19 ARDS showed rapid and significant improvement in inflammation and oxygenation within 9 days of treatment commencing, as opposed to typical 14-20 days. Significant reduction in inflammatory and thromboembolic markers, and improved major respiratory markers. Non-controlled study. Markers are compared from before and after treatment.
- A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19 in Wiley Journal of Medical Virology. Two severe covid-19 patients received adjunct ozone major auto-haemotherapy, contrasted with two similar patients who didn’t.
- Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study (preprint from medRxiv, not peer reviewed) 9 patients treated with autohaemotherapy vs 9 control: treatment group had dramatically shorter time to clinical improvement (median 7 days vs median 28 days for control group) and a much higher proportion that achieved 14-day clinical improvement (88% vs 33%).
- A Novel Approach to Treating COVID-19 Using Nutritional and Oxidative Therapies. Not sure if this is peer reviewed. Results of 107 Covid-19 patients treated in a private clinic with various nutritional and oxidative therapies.
- Complementary Application of the Ozonized Saline Solution in Mild and Severe Patients with Pneumonia Covid-19: A Non-randomized Pilot Study. Non-randomized, non-controlled with 25 participants. Looking mainly at safety.
- Potential Role of Oxygen-Ozone Therapy in Treatment of COVID-19 Pneumonia. Case report: 3 COVID-19 pneumonia patients with respiratory failure showed improved hypoxia and decreased inflammatory markers and D-dimer immediately after 1 to 4 sessions of ozone therapy. All 3 were released home 3 – 4 days after first treatment. None required invasive mechanical ventilation.
- Novel therapy for COVID-19 does intravenous ozonatedsaline affect blood and tissue oxygenation? Prospective, controlled pilot study on a single person found that ozonated saline infusion increased how long a subject can remain in hypoxia.
- Use of Ozone as an adjuvant therapy for patients with COVID-19 in Iraq: a comparison study with studies from other countries Poorly written, uncontrolled, and with vaguely described results. 98 patients aged 21-78: 82 in “moderate” or “severe” stages and 16 in “critical” stage. Treatment was ozonated saline for 5-10 days (1 or 2 treatments per day) then “followed up” (?) for 4 weeks. 10 critical patients died before 5 doses could be administered, but all other patients recovered (recovery period not stated) and tested negative after 2 weeks.
- Case Report: Recovery of One ICU-Acquired COVID-19 Patient Via Ozonated Autohemotherapy Detailed case report for one COVID-19 patient with severe ARDS who received 5 days of autohaemotherapy and recovered.
- Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience A small, non-randomized retrospective study of autohaemotherapy on 30 in treatment group vs 30 in control group (all received best available treatments). Clinical improvement was somewhat better in the treatment group, but results are hard to interpret given that the treatment group tended to be younger but with more severe symptoms at outset.
Study results reporting ambivalent or negative outcomes:
- Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial Prospective randomized study on ozone autohaemotherapy for COVID-19 stage III patients, comparing 14 in the treatment group against 14 controls (all received best available treatments). The treatment was found to be safe and non-toxic, but did not significantly influence mortality, need for ventilation, inflammation markers, haematology profile or lymphocite levels.
Proposals, discussions of potential mechanisms, etc:
- Review: Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19 in MDPI Journal Antioxidants 2020. Mainly focused on ozone as a modulator of the NF-κ B/Nrf2 pathways and IL-6/IL-1β expression.
- Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19. A letter to the editor in European Review for Medical and Pharmacological Sciences
- Editorial: Ozone as a complement therapy in the treatment of COVID-19 in Revista Brasileira de Fisiologia do Exercício
- Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study. (Epub ahead of print) In Biolife Sas Journal of Biological Regulators and Homeostatic Agents.
- Ozone therapy as an adjunct in the treatment to COVID-19. Brazilian Journal of Exercise Physiology
- Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review: In STM journal Medical Gas Research.
- Ozone Autohemotherapy: Possible Mechanisms of Anti-Viral Action and Anti Oxidative: In ClinMed J Infect Dis Epidemiol. Antiviral, anti-oxidative, anti-inflammatory, cytokine-regulating, improving blood rheology, oxygen utilisation, vasodilation.
Email I sent to NZ medical authorities 13 April 2020:
- Santa María della Misericordia University Hospital, Udine, Italy: Of thirty-six covid-19 patients, each of whom had developed pneumonia and severe respiratory difficulty, all but one showed rapid reversal following IV ozone treatment. These 35 did not need to enter intensive care or be intubated, and have since returned to their families (Reported 5 April, https://
messaggeroveneto.gelocal.it/ udine/cronaca/2020/04/05/news/ pazienti-curati-con-l-ozono- su-36-solo-uno-e-intubato-1. 38681628 — translation below). - Two hospitals in Bergamo: Of 11 patients in serious or very serious condition (4 intubated, 7 not), 10 showed rapid and decisive improvement. One patient died, though this patient had already been in a severely compromised state when ozone treatment was begun as a last-ditch attempt. The researchers say that no covid-19 patients are showing as rapid and stable improvement as those receiving ozone therapy (Reported 1 April, http://www.
ossigenoozono.it/EN/News/3507/ COVID-19_PATIENTS_IMPROVED_ WITH_OXYGEN_OZONE_THERAPY). - Nuestra Señora del Rosario Polyclinica, Ibiza, Spain: “Many” patients who were on the verge of being intubated showed “spectacular” rapid improvement to the point of not requiring oxygen. The Spanish team has registered a clinical trial but urges the rest of the world to begin using ozone therapy as soon as possible. (Reported 8 April, https://www.
diariodeibiza.es/pitiuses- balears/2020/04/08/la- policlinica-trata-exito-los/ 1135505.html; and https://theibizan.com/ ozone-patient-expresses- thanks/)
- Direct oxidation of sulfhydral groups in the virion’s spikes, neutralising the virus in the bloodstream.
- Cytokine regulation: Ozonides in the bloodstream induce the synthesis of 4-hydroxynonenal (4-HNE) which in turn induces anti-inflammatory cytokines and suppresses pro-inflammatory cytokines, preventing cytokine storm.
- Stimulates increased release of immune-active cytokines, via NFAT transcription factors.
- Anti-thrombotic activity as result of ozonides stimulating endothelial cells to release nitroxide (NO), which in turn acts to reduce blood viscosity and platelet aggregation and increases availability of oxyhaemoglobin to cells. Diffuse thrombosis is a major factor in covid-19 deaths.
- Dr. Jose Baeza-Noci, President of the Spanish Society of Ozone Therapy and Vice President of the World Federation of Ozone Therapy: mailto://editor-in-
chief@journalofozonetherapy. org - Dr. Francisco Vilás, CEO of Nuestra Señora del Rosario Polyclinica. Contact the hospital +34 971 30 19 16 or mailto://info@
grupopoliclinica.es.
Italian group:
- Prof. Marianno Franzini, Società Scientifica di Ossigeno-Ozono Terapia (SIOOT): info@ossigenoozono.it
Only one of the thirty-six Covid-19 patients treated with ozone has entered intensive care and is intubated. All the others, despite having developed pneumonia and severe respiratory difficulties, have shown a reversal and, shortly, will return to their families. The results are there for all to see: the Anesthesia and Resuscitation Team together with that of the Infectious Diseases of the Central Friuli University Health Authority, led by the anesthesiologist Amato De Monte and the infectious disease specialist Carlo Tascini, await authorization from the Italian Medicines Agency (Aifa) and the Ethics Committee of the Spallanzani Institute of Rome to start a prospective randomized and controlled study. The goal is to evaluate the effectiveness of ozone treatment in patients who have developed coronavirus infection.The clinical study will be carried out with other Italian centers that believe in the therapy developed in the Santa Maria della Misericordia hospital, by the director of the Department of Anesthesia and Resuscitation and by the Professor of Infectivology at the University of Friuli. Alongside De Monte and Tascini there are also Mattia Buttazzoni, Cristiana Macor, Carola Martellon, Ermal Rica, Giovanni Sermann and the staff of the inter-company analysis laboratory directed by Professor Francesco Curcio.
It is a close-knit team, engaged for weeks in an exchange of knowledge that has lit a light in the coronavirus tunnel. He indicated a path that could — the conditional is important — lead to a therapy that in the worst case does not give results, does not cause side effects and does not compromise the results of other therapies used so far. But if, as has been found in the 36 patients treated, it is established that the use of ozone significantly reduces entries into the intensive care units, the turning point could write a page of history in the fight against the novel virus.
In Udine, in the 36 patients undergoing ozone therapy, the percentage of intubated patients fell from 15 to 3 percent. In itself, the treatment is simple: “We take 200 ml of blood which we let interact for about ten minutes with the ozone and then re-inject it into the patient.”
“The procedure must be repeated three, four times at most” explain De Monte and Tascini in pointing out that the therapy is cheap and avoids ending up in the intensive care unit where the greatest number of deaths occurs. In these cases, prudence is never too much even if the initial results bode well. “The clinical study” – adds Tascini – “will allow us to verify whether ozone-based infusion therapy can restore the immune system.”
Second report of the Italian Scientific Society of Oxygen Ozone Therapy (SIOOT), as translated by the UK Ozone Society:
Further reports and news items:
http://www.ossigenoozono.it/IT/News/3506/PRIMO_REPORT_-_OSSIGENO_OZONO_SIOOT_NEI_PAZIENTI_RICOVERATI_CON_COVID-19
FIRST REPORT ON THE USE OF SIOOT OZONE OXYGEN IN RECOVERED PATIENTS WITH COVID-19
Bergamo, April 1, 2020
TREATED PATIENTS 11
INTUBATED PATIENTS 4
NON-INTUBATED PATIENTS 7
5 DAYS OF TREATMENT – 1 GAEI PER DAY
EXTUBATED PATIENTS 1
PATIENTS CURRENTLY INTUBATED 2
PATIENTS NOT INTUBATED WITH OXYGEN NON-INVASIVE THERAPY 6
PATIENTS INTUBATED AND DEAD FROM BACTERIAL SUPERINFECTION AND SEPTIC SHOCK 1
HEALED PATIENTS WITH TWO NEGATIVE SWABS 1
After the 5 treatments with SIOOT Ozone Ozone Therapy, excluding the only deceased, we observed:
1. General improvement of clinical conditions
2. Normalization of body temperature (fever)
3. Reduction of PCR (reactive protein C)
4. Normalization of heart rate
5. Improvement of saturation and reduction of oxygen support
6. Normalization of renal function (creatinine)
After the 5 treatments carried out we recommend:
– Continue Oxygen Ozone Therapy treatment, carefully respecting the SIOOT protocol.
– Recommended examinations for the follow-up of each patient (PCD, LDH, INTERLEUCHINE as far as possible, CREATININE, ELECTROLYTES, GLYCEMIA)
– Continue with the drug therapy already set
PLEASE SEND WEEKLY, BY MONDAY ON
REPORT OF TREATED PATIENTS.
http://www.ossigenoozono.it/IT/News/3508/SECONDO_REPORT_-_OSSIGENO_OZONO_SIOOT_NEI_PAZIENTI_RICOVERATI_CON_COVID-19
Second report on SIOOT oxygen ozone in 46 patients, from the least serious to the most serious with covid-19. Of these, 39 patients significantly improved.
Patients treated: 46
Intubated patients: 11
Non intubated patients: 35
Average of 5 oxygen ozone therapy treatments
Extubated patients: 6
Currently intubated patients: 3
Patients who have not had to be intubated: 28
Intubated and deceased patients from bacterial superinfection, septic shock, pulmonary embolism and myocarditis (2 treatments): 4
Patients recovered with two negative swabs: 5
N.B. The currently available data is that SIOOT oxygen ozone therapy is indicated mainly for patients before intubation.
It is confirmed that:
1. General improvement of clinical conditions.
2. Normalization of body temperature.
3. Reduction of PCR (reactive protein C).
4. Normalization of heart rate.
5. Improvement of saturation and reduction of oxygen support
6. Normalization of renal function (creatinine)
7. Increase in leukocytes
Bergamo, 9/04/2020
Sharing clinical trial data is in everyone’s interest: patients, clinicians, regulatory authorities
http://backoffice.ossigenoozono.it/Multimedia/Content/TERZO_REPORT_-_24042020.pdf
THIRD REPORT ON OXYGEN OZONE SIOOT
In 73 patients, from least to most serious with COVID-19.
Of these, 61 decisively improved patients.
TREATED PATIENTS: 73 (24 intubated, 49 non-intubated)
AVERAGE OF 5 OXYGEN OZONE THERAPY TREATMENTS
- Extubated patients: 15
- Patients still intubated: 5
- Patients who did not require intubation: 36
- Patients intubated and dead from bacterial superinfection, septic shock, pulmonary embolism and myocarditis (2 treatments): 7
- Recovered patients with two negative swabs: 10
N.B. The immediately noticeable data is that SIOOT Oxygen Ozone Therapy
is mainly indicated in phase 1 and 2 patients, and in any case
before intubation. These data suggest that if the intervention were done at home it would have even greater success than at present.
It is reconfirmed:
1. General improvement of clinical conditions
2. Normalization of body temperature
3. Reduction of PCR (reactive protein C)
4. Normalization of heart rate
5. Improvement of saturation and reduction of oxygen support
6. Normalization of renal function (creatinine)
7. Increased leukocytes and lymphocytes
Bergamo, 24/04/2020
Sharing clinical trial data is in everyone’s interest: PATIENTS, CLINICS, REGULATORY AUTHORITIES
Prof. Luigi Valdenassi Prof. Marianno Franzi
Initial average value | After 3-4 treatments with O2O3 | |
---|---|---|
Body temperature | 37.7° – 38.7° | 36° – 36.5° |
Cardiac Fr | 90 – 100 | 70 – 75 |
S. O2: intubated | <70 | intubated |
S. O2: Not Intubated | 80 – 85 | 92 – 95 |
Blood sugar | 200 – 300 | 90 -150 |
Transaminases | 90 – 250 | 40 – 50 |
Creatinine | 1.5 – 3.5 | 1 – 1.3 |
Electrolytes: Na – K –Ca | < the norm | In the norm |
Leukotics | 3,000 – 4,000 | > 5,500 |
Lymphocytes | Very serious <3 | very serious <7 |
Serious <10 | Serious 10 – 20 | |
Moderate 10 – 15 | Moderate 15 – 20 | |
Slight 15 – 20 | Slight 25 – 30 | |
PCR | 10 – 200 | <10 |
LDH | 300 – 350 | <250 |
Didimero | 600 – 2000 | 400 – 500 |
Didymero> 3,000 | 8,000 – 15,000 | Thromboembolism |
Procalcitonin | <0.5 ng / ml | <0.05 |
Procalcitonin | > 5 ng / ml | Superinfection |
Associated therapy: in the judgment of the attending physician
Observation: Patients not treated with associated ozone therapy had a slower recovery. We observed that patients with seasonal flu shots had significant symptoms.
Clinical evolution with improvement of cardiac function.
EARLY GAE: (1st-2nd day hospitalization) COVID19 confirmed | ==> | Patients: Serious, moderate, mild | ==> | Clinical evolution without neurological complications. UNHARMED. |
EARLY GAE: (1st-2nd day hospitalization) COVID19 confirmed | ==> | Patients with MYOCARDITIS (ELECTROCARDIOGRAM) | ==> | Clinical evolution with improvement of cardiac function. |
O2O3 protocol: Method according to the provisions of SIOOT in the 5 phases
O2O3 materials:
– Multiossigen Medical 95 CPS device
– SANO3 bag, specially certified
N° Patients: Total 80: 40 with O3 and 40 without
Report 5
15 May 2020
HEMATOCLINICAL DATA DEMONSTRATE THE EFFECTIVENESS OF OXYGEN OZONE THERAPY WITH SIOOT PROTOCOL IN THE TREATMENT OF COVID19
Number of patients: 40 | Number of patients: 40 | |||||
PATIENTS TREATED WITH STANDARD THERAPY + SIOOT OXYGEN OZONE | PATIENTS TREATED ONLY WITH STANDARD THERAPY | |||||
---|---|---|---|---|---|---|
Average initial value | After 3-4 treatments O2O3 | Average% | Average initial value | Final value after 15 days | Average % | |
Body temperature | 38.7 | 36.5 | -5% | 38.6 | 37.9 | -2% |
Blood sugar | 300 | 150 | -50% | 171 | 134 | -25% |
Creatinine | 3.5 | 1.3 | -60% | 1.27 | 1.50 | +15% |
Leukotics | 3000 | 5500 | +80% | 6379 | 8354 | +31% |
Lymphocytes1 | 15 | 30 | +100% | 15.48 | 21.38 | +40% |
PCR | 10 | <10 | -50% | 7.46 | 5.97 | -20% |
D-didimer2 | 1300 | 500 | -54% | 1020 | 939 | -10% |
1More lymphocytes means immune response / capacity
2High D-dimer levels → TEP (pulmonary embolism / microthrombosis) risk → death risk
Associated therapy: in the judgment of the attending physician
Observation: Patients not treated with Oxygen Ozone Therapy had a slower recovery*1
EARLY GAEI: (1st-2nd day hospitalization) COVID19 confirmed | → | Patients: Serious / moderate / mild | → | Clinical evolution without neurological complications. Cured. |
EARLY GAEI: (1st-2nd day hospitalization) COVID19 confirmed | → | Patients with PERICARDITIS/MYOCARDITIS (forms of microvasculitis). ELECTROCARDIOGRAM | → | Clinical evolution with improvement of cardiac function. |
O2O3 protocol:
Method according to the provisions of SIOOT in the 5 stages
O2O3 materials:
– Equipment with ozonation tubes of minimum length of 60 cm, A.T. transformers producing at least 16,000 volts, oxygen flow variable from 1 to 10 liters.
– SANO3 bag, specially certified without phthalates.
*1Slower response and > late complication with metabolic syndrome (renal failure, microthrombosis, fever)
https://www.farodiroma.it/nei-casi-di-covid-19-lossigeno-ozono-e-altamente-efficace-ce-un-miglioramento-in-tutti-i-pazienti-trattati/
Gives more detail regarding the second SIOOT report. Excerpts:
“Together with prof. Luigi Valdenassi, national president of SIOOT, Franzini is collecting and analyzing data from the 20 hospitals that are currently treating people affected by Covid-19 in Italy according to the medical protocol of ozone therapy formulated by SIOOT.”
“Yesterday the data arrived for 46 patients, hospitalized in 6 different hospitals, who were treated with 5 sessions of Oxygen Ozone Therapy. Analyzing the parameters it turns out that ozone oxygen is highly effective. There is a rapid and evident improvement in all treated patients. Of the 11 intubated and intensive care patients, 6 were extubated after ozone oxygen treatment, 1 improved, while 4 died before being able to practice the entire ozone therapy cycle. Prof. explained Franzini that the conditions of the four deceased patients were very serious. They suffered from bacterial superinfection, septic shock, pulmonary embolism and myocarditis. ‘By studying the medical records’, Franzini said, ‘I was able to observe the lung plates and I swear I have never seen lungs so compromised’.”
“Thanks to ozone oxygen treatment, 28 patients improved significantly and did not need to be intubated. 5 patients who, after 5 ozone therapy sessions tested negative for the double tampon, have already returned home. There are still 3 ICU patients who continue to be treated with oxygen, ozone. Franzini has specified that, from the cross comparison of the analyzes, confirmation is obtained that the oxygen ozone has managed to improve the health conditions of all patients undergoing therapy. Based on these findings, the international president of SIOOT argued that the time has come for a change of pace in the virus contrast strategy. ‘Experience is telling us’, he stressed, ‘that the Covid-19 virus must be attacked immediately when it is weaker, for this reason, people who are positive should be treated immediately. Starting with those who are at home in quarantine’. ‘We understand’, he added, ‘that leaving people at home waiting for fever and other symptoms to occur is very dangerous, because once the virus has attacked the lungs, the circulatory and kidney systems, it becomes more difficult to deactivate it.’.”
http://backoffice.ossigenoozono.it/Multimedia/Content/Oxygen-ozone_immunoceutical_therapy_in_COVID-19_outbreak_facts_and_figures.pdf
Oxygen-ozone immunoceutical therapy in COVID-19 outbreak: facts and figures
Giovanni Ricevuti, Marianno Franzini, Luigi Valdenassi
Ozone Therapy 2020 5:9014
Facebook post: “Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19” has been accepted for publication in European Review for Medical and Pharmacological Sciences.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3561379
Case Report: Recovery of One ICU-Acquired COVID-19 Patient Via Ozonated Autohemotherapy
Wu Junping et al.
Haihe Hospital, Tianjin University, China
https://www.agronline.it/sanita/l-ozonoterapia-puo-combattere-il-covid-19-primi-risultati-positivi-di-uno-studio-italiano_19315
A news article describing the relation of SIOOT with China and how Prof. Dong Ming of Tianjin University has developed a protocol yielding positive results.
https://www.orbisphera.org/Pages/PrimoPiano/1995/Il_Collegio_Medico_dell%E2%80%99Universit%C3%A0_di_Tianjin_conferma_che_l%E2%80%99Ossigeno_Ozono_Terapia_%C3%A8_efficace_contro_il_Covid-19
THE MEDICAL COLLEGE OF TIANJIN UNIVERSITY CONFIRMS THAT OXYGEN OZONE THERAPY IS EFFECTIVE AGAINST COVID-19
Notes regarding safety
Direct intravenous and intra-arterial injection of O2/O3 gas used to be widely practiced in Germany in the 1970s and early 1980s and has a history of serious side-effects, including death. In each case the clinical picture was consistent with either gas embolism or allergic shock. This method of delivery is now considered malpractice by most (though not all) practitioners.
One case of apparent allergic shock following a very small amount of gas injected raises the unknown possibility that other forms of delivery such as autohaemotherapy could also carry a risk of allergic shock.
One case of heart attack has been noted, which followed some hours after a major autohaemotherapy; but the contribution of the therapy in this case is disputed. There have also been reports of hepatitis C being transmitted by ozone therapy.
Otherwise, there seems little report of adverse effects. Ro and Rowen claim they have between them performed over 60,000 major autohaemotherapies over 30 years with no side effects.
Notes on the infamous German safety study